Summary

US Ophthalmic Drugs Market is valued at approximately USD 11.93 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.69% over the forecast period 2024-2032. Ophthalmic drugs represent a specialized class of medications crafted to address a myriad of eye ailments and conditions. These therapeutic agents offer versatile delivery methods, including eye drops, ointments, gels, and injections, tailored to suit individual needs. They serve as invaluable tools in the management of diverse ocular concerns spanning from infections and inflammation to glaucoma, allergies, dry eye syndrome, and beyond, ensuring comprehensive care for eye health. Also, technological advancements in drug delivery systems, such as sustained-release implants, punctal plugs, and nanotechnology-based formulations, are enhancing the effectiveness and convenience of ophthalmic drug therapies. These innovations are attracting both patients and healthcare providers, thereby support the growth of Ophthalmic Drugs Market.

Moreover, the rising prevalence of eye disorders such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts is driving the demand for ophthalmic drugs. As the population ages and chronic conditions become more prevalent, the need for treatments for these diseases grows. Also, the increasing healthcare expenditure in the US, coupled with better access to healthcare services, allows more patients to seek treatment for eye disorders, thereby driving the demand for ophthalmic drugs. However, the risks associated with ophthalmic pharmaceuticals, as well as the longer timeline required for ophthalmic drug development, are projected to impede market expansion in the Ophthalmic drugs Market during 2024 to 2032.

Major market player included in this report are:
Bausch Health Companies Inc.
Merck & Co., Inc
Genentech, Inc.
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Drug Class
Anti-glaucoma Drugs
Dry Eye Drugs
Ophthalmic Anti-allergy/Inflammatory
Retinal Drugs
Anti-infective Drugs
Other Drugs

By Product Type
OTC Drugs
Prescription Drugs

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. US Ophthalmic Drugs Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Ophthalmic Drugs Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Drug Class
2.2.2. By Product Type
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Ophthalmic Drugs Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Ophthalmic Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Ophthalmic Drugs Market Size & Forecasts by Drug Class 2022-2032
5.1. Anti-glaucoma Drugs
5.2. Dry Eye Drugs
5.3. Ophthalmic Anti-allergy/Inflammatory
5.4. Retinal Drugs
5.5. Anti-infective Drugs
5.6. Other Drugs
Chapter 6. US Ophthalmic Drugs Market Size & Forecasts by Product Type 2022-2032
6.1. OTC Drugs
6.2. Prescription Drugs
Chapter 7. Competitive Intelligence
7.1. Key Company SWOT Analysis
7.1.1. Company 1
7.1.2. Company 2
7.1.3. Company 3
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Bausch Health Companies Inc.
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Market Strategies
7.3.2. Merck & Co., Inc
7.3.3. Genentech, Inc.
7.3.4. Company 4
7.3.5. Company 5
7.3.6. Company 6
7.3.7. Company 7
7.3.8. Company 8
7.3.9. Company 9
7.3.10. Company 10
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes